 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 January 1997 | Volume 126 Issue 1 | Pages 1-12
Background: Implantable cardioverter defibrillators (ICDs) are remarkably effective in terminating ventricular arrhythmias, but they are expensive and the extent to which they extend life is unknown. The marginal cost-effectiveness of ICDs relative to amiodarone has not been clearly established.
Objective: To compare the cost-effectiveness of a third-generation implantable ICD with that of empirical amiodarone treatment for preventing sudden cardiac death in patients at high or intermediate risk.
Design: A Markov model was used to evaluate health and economic outcomes of patients who received an ICD, amiodarone, or a sequential regimen that reserved ICD for patients who had an arrhythmia during amiodarone treatment.
Measurements: Life-years gained, quality-adjusted life-years gained, costs, and marginal cost-effectiveness.
Results: For the base-case analysis, it was assumed that treatment with an ICD would reduce the total mortality rate by 20% to 40% at 1 year compared with amiodarone and that the ICD generator would be replaced every 4 years. In high-risk patients, if an ICD reduces total mortality by 20%, patients who receive an ICD live for 4.18 quality-adjusted life-years and have a lifetime expenditure of $88 400. Patients receiving amiodarone live for 3.68 quality-adjusted life-years and have a lifetime expenditure of $51 000. Marginal cost-effectiveness of an ICD relative to amiodarone is $74 400 per quality-adjusted life-year saved. If an ICD reduces mortality by 40%, the cost-effectiveness of ICD use is $37 300 per quality-adjusted life-year saved. Both choice of therapy (an ICD or amiodarone) and the cost-effectiveness ratio are sensitive to assumptions about quality of life.
Conclusions: Use of an ICD will cost more than $50 000 per quality-adjusted life-year gained unless it reduces all-cause mortality by 30% or more relative to amiodarone. Current evidence does not definitively support or exclude a benefit of this magnitude, but ongoing randomized trials have sufficient statistical power to do so.
ARTICLE
Cost-Effectiveness of Implantable Cardioverter Defibrillators Relative to Amiodarone for Prevention of Sudden Cardiac Death
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  C. R. Cooke, J. M. Kahn, T. R. Watkins, L. D. Hudson, and G. D. Rubenfeld Cost-effectiveness of Implementing Low-Tidal Volume Ventilation in Patients With Acute Lung Injury Chest, July 1, 2009; 136(1): 79 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gasparini, C. Menozzi, A. Proclemer, M. Landolina, S. Iacopino, A. Carboni, E. Lombardo, F. Regoli, M. Biffi, V. Burrone, et al. A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft VentriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study Eur. Heart J., June 29, 2009; (2009) ehp247v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C McKenna, S Palmer, M Rodgers, D Chambers, N Hawkins, S Golder, S Van Hout, C Pepper, D Todd, and N Woolacott Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom Heart, April 1, 2009; 95(7): 542 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62. [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons Circulation, May 27, 2008; 117(21): e350 - e408. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A Hlatky, D. K Owens, and G. D Sanders Cost-effectiveness as an outcome in randomized clinical trials Clinical Trials, December 1, 2006; 3(6): 543 - 551. [Abstract] [PDF]
|
|
|
|
|
|
P. S. Chan, K. Stein, T. Chow, M. Fendrick, J. T. Bigger, and S. Vijan Cost-Effectiveness of a Microvolt T-Wave Alternans Screening Strategy for Implantable Cardioverter-Defibrillator Placement in the MADIT-II-Eligible Population J. Am. Coll. Cardiol., July 4, 2006; 48(1): 112 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Sanders, M. A. Hlatky, and D. K. Owens Cost-Effectiveness of Implantable Cardioverter-Defibrillators N. Engl. J. Med., October 6, 2005; 353(14): 1471 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kadish and M. Mehra Heart Failure Devices: Implantable Cardioverter-Defibrillators and Biventricular Pacing Therapy Circulation, June 21, 2005; 111(24): 3327 - 3335. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Al-Khatib, K. J. Anstrom, E. L. Eisenstein, E. D. Peterson, J. G. Jollis, D. B. Mark, Y. Li, C. M. O'Connor, L. K. Shaw, and R. M. Califf Clinical and Economic Implications of the Multicenter Automatic Defibrillator Implantation Trial-II Ann Intern Med, April 19, 2005; 142(8): 593 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Weintraub, Z. Zhang, E. M. Mahoney, P. Kolm, J. A. Spertus, J. Caro, J. Ishak, R. Goldberg, J. Tooley, R. Willke, et al. Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure Circulation, March 8, 2005; 111(9): 1106 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Shrive, B. J. Manns, P. D. Galbraith, M. L. Knudtson, W. A. Ghali, and for The APPROACH Investigators Economic evaluation of sirolimus-eluting stents Can. Med. Assoc. J., February 1, 2005; 172(3): 345 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Hlatky, G. D. Sanders, and D. K. Owens Evidence-Based Medicine And Policy: The Case Of The Implantable Cardioverter Defibrillator Health Aff., January 1, 2005; 24(1): 42 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Nichol, P. Kaul, E. Huszti, and J. F.P. Bridges Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Symptomatic Heart Failure Ann Intern Med, September 7, 2004; 141(5): 343 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. DiMarco Implantable Cardioverter-Defibrillators N. Engl. J. Med., November 6, 2003; 349(19): 1836 - 1847. [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Antezano and M. Hong Sudden Cardiac Death J Intensive Care Med, November 1, 2003; 18(6): 313 - 329. [Abstract] [PDF]
|
|
|
|
|
|
G. Nichol, T. Valenzuela, D. Roe, L. Clark, E. Huszti, and G.A. Wells Cost Effectiveness of Defibrillation by Targeted Responders in Public Settings Circulation, August 12, 2003; 108(6): 697 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Boriani, M. Biffi, C. Martignani, C. Camanini, F. Grigioni, C. Rapezzi, and A. Branzi Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs Eur J Heart Fail, August 1, 2003; 5(4): 419 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
National Emphysema Treatment Trial Research Group Cost Effectiveness of Lung-Volume-Reduction Surgery for Patients with Severe Emphysema N. Engl. J. Med., May 22, 2003; 348(21): 2092 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Strickberger, J. D. Hummel, T. G. Bartlett, H. I. Frumin, C. D. Schuger, S. L. Beau, C. Bitar, F. Morady, and AMIOVIRT Investigators Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemicdilated cardiomyopathy and asymptomaticnonsustained ventricular tachycardia--AMIOVIRT J. Am. Coll. Cardiol., May 21, 2003; 41(10): 1707 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ezekowitz, P. W. Armstrong, and F. A. McAlister Implantable Cardioverter Defibrillators in Primary and Secondary Prevention: A Systematic Review of Randomized, Controlled Trials Ann Intern Med, March 18, 2003; 138(6): 445 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Morris Meeting Unmet Needs in Patients With Sepsis: the Role of Drotrecogin Alfa (Activated) Am. J. Crit. Care., March 1, 2003; 12(2): 94 - 97. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Donaldson Jr., E. C. Stecker, H. A. Pollack, E. V. Carbajal, R. G. Smith, S. E. Cohen, A. K. Gollapudi, C. Spivack, A. J. Moss, W. J. Hall, et al. Implantable Cardiac Defibrillators N. Engl. J. Med., August 1, 2002; 347(5): 365 - 367. [Full Text] [PDF]
|
|
|
|
|
|
G. D. Sanders, M. A. Hlatky, N. R. Every, K. M. McDonald, P. A. Heidenreich, L. S. Parsons, and D. K. Owens Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction Ann Intern Med, November 20, 2001; 135(10): 870 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sheldon, B. J. O'Brien, G. Blackhouse, R. Goeree, B. Mitchell, G. Klein, R. S. Roberts, M. Gent, and S. J. Connolly Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator: The Canadian Implantable Defibrillator Study Circulation, October 2, 2001; 104(14): 1622 - 1626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Groeneveld, J. L. Kwong, Y. Liu, A. J. Rodriguez, M. P. Jones, G. D. Sanders, and A. M. Garber Cost-effectiveness of Automated External Defibrillators on Airlines JAMA, September 26, 2001; 286(12): 1482 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Boriani, M Biffi, C Martignani, M Gallina, and A Branzi Cost-effectiveness of implantable cardioverter-defibrillators Eur. Heart J., June 2, 2001; 22(12): 990 - 996. [PDF]
|
|
|
|
|
|
M. H. Gollob and J. J. Seger Current Status of the Implantable Cardioverter-Defibrillator Chest, April 1, 2001; 119(4): 1210 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Hallstrom, J. H. McAnulty, B. L. Wilkoff, D. Follmann, M. H. Raitt, M. D. Carlson, A. M. Gillis, H.-T. Shih, J. L. Powell, H. Duff, et al. Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1093 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. O'Brien, S. J. Connolly, R. Goeree, G. Blackhouse, A. Willan, R. Yee, R. S. Roberts, and M. Gent Cost-Effectiveness of the Implantable Cardioverter-Defibrillator : Results From the Canadian Implantable Defibrillator Study (CIDS) Circulation, March 13, 2001; 103(10): 1416 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nisam A Prophylactic ICD? Who are the patients? What is the device? Europace, January 1, 2001; 3(4): 269 - 274. [PDF]
|
|
|
|
|
|
A.J Camm and S Nisam The Utilization of the Implantable Defibrillator--a European Enigma Eur. Heart J., December 2, 2000; 21(24): 1998 - 2004. [PDF]
|
|
|
|
 |
|
 M. S. Kocher, G. Erens, T. S. Thornhill, and J. E. Ready Cost and Effectiveness of Routine Pathological Examination of Operative Specimens Obtained During Primary Total Hip and Knee Replacement in Patients with Osteoarthritis J. Bone Joint Surg. Am., November 1, 2000; 82(11): 1531 - 1531. [Abstract] [Full Text]
|
|
|
|
|
|
P.R. Roberts, T.R. Betts, and J.M. Morgan Cost effectiveness of the implantable cardioverter defibrillator Eur. Heart J., May 1, 2000; 21(9): 712 - 719. [PDF]
|
|
|
|
|
|
R. Sheldon, S. Connolly, A. Krahn, R. Roberts, M. Gent, and M. Gardner Identification of Patients Most Likely to Benefit From Implantable Cardioverter-Defibrillator Therapy : The Canadian Implantable Defibrillator Study Circulation, April 11, 2000; 101(14): 1660 - 1664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Sanders, R. F. Nease JR, and D. K. Owens Design and Pilot Evaluation of a System to Develop Computer-based Site-specific Practice Guidelines from Decision Models Med Decis Making, April 1, 2000; 20(2): 145 - 159. [Abstract] [PDF]
|
|
|
|
|
|
M. S. Stanton and G. K. Bell Economic Outcomes of Implantable Cardioverter-Defibrillators Circulation, March 7, 2000; 101(9): 1067 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Calkins, J. T. Bigger Jr, S. J. Ackerman, S. B. Duff, D. Wilber, R. A. Kerr, M. Bar-Din, K. M. Beusterien, and M. J. Strauss Cost-Effectiveness of Catheter Ablation in Patients With Ventricular Tachycardia Circulation, January 25, 2000; 101(3): 280 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Teerlink, M. Jalaluddin, S. Anderson, M. L. Kukin, E. J. Eichhorn, G. Francis, M. Packer, and B. M. Massie Ambulatory Ventricular Arrhythmias in Patients With Heart Failure Do Not Specifically Predict an Increased Risk of Sudden Death Circulation, January 4, 2000; 101(1): 40 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Catherwood, W. D. Fitzpatrick, M. L. Greenberg, P. T. Holzberger, D. J. Malenka, B. R. Gerling, and J. D. Birkmeyer Cost-Effectiveness of Cardioversion and Antiarrhythmic Therapy in Nonvalvular Atrial Fibrillation Ann Intern Med, April 20, 1999; 130(8): 625 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Sanders, C. G. Hagerty, F. A. Sonnenberg, M. A. Hlatky, and D. K. Owens Distributed Decision Support Using a Web-based Interface: Prevention of Sudden Cardiac Death Med Decis Making, April 1, 1999; 19(2): 157 - 166. [Abstract] [PDF]
|
|
|
|
|
|
A. I. Mushlin, W. J. Hall, J. Zwanziger, E. Gajary, M. Andrews, R. Marron, K. H. Zou, and A. J. Moss The Cost-effectiveness of Automatic Implantable Cardiac Defibrillators: : Results From MADIT Circulation, June 2, 1998; 97(21): 2129 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. GLASZIOU Using cost-effectiveness for subsidy decisions Heart, January 1, 1998; 79(1): 7 - 8. [Full Text] [PDF]
|
|
|
|
|
|
G. Larsen, A. Hallstrom, J. McAnulty, S. Pinski, A. Olarte, S. Sullivan, M. Brodsky, J. Powell, C. Marchant, C. Jennings, et al. Cost-Effectiveness of the Implantable Cardioverter-Defibrillator Versus Antiarrhythmic Drugs in Survivors of Serious Ventricular Tachyarrhythmias: Results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Economic Analysis Substudy Circulation, April 30, 2002; 105(17): 2049 - 2057. [Abstract] [Full Text] [PDF]
|
|
